Related Experiment Video

Updated: Jun 16, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

HLA class II polymorphisms in Tunisian patients with dilated cardiomyopathy

S Mahjoub1, S Mehri, E Ghazouani

  • 1Unité d'Epidémiologie Génétique et Moléculaire, Faculté de Médecine de Tunis, Tunis, Tunisia.

Tissue Antigens
|February 9, 2010
PubMed

Insights

Certain human leukocyte antigen (HLA) class II alleles are linked to dilated cardiomyopathy (DCM) susceptibility in Tunisians. Specific HLA-DRB1 and HLA-DQB1 variations increase or decrease the risk of developing this heart muscle disorder.

Area of Science:

  • Immunogenetics
  • Cardiology
  • Human Genetics

Background:

  • Cardiomyopathies (CMs) are primary cardiac muscle disorders leading to heart failure and mortality.
  • Genetic factors play a crucial role in the pathogenesis of CMs, including dilated cardiomyopathy (DCM).
  • Class II major histocompatibility complex (MHC) genes, specifically human leukocyte antigen (HLA)-DRB1 and HLA-DQB1, are investigated for their role in immune response and disease susceptibility.

Purpose of the Study:

  • To investigate the association between class II HLA-DRB1 and HLA-DQB1 alleles and the genetic susceptibility to primary dilated cardiomyopathy (DCM).
  • To identify specific HLA alleles and haplotypes that confer risk or protection against DCM in the Tunisian population.

Main Methods:

  • Genotyping of HLA-DRB1 and HLA-DQB1 alleles using polymerase chain reaction-sequence specific primers (PCR-SSP).
  • Analysis of allele and haplotype frequencies in 76 Tunisian patients with primary DCM and 111 healthy controls.
  • Statistical analysis including odds ratios (OR) and P-values to determine the significance of associations.

Main Results:

  • Increased frequencies of HLA-DRB1*0401, HLA-DQB1*0302, and HLA-DQB1*0401 alleles were observed in DCM patients compared to controls.
  • Specific alleles, HLA-DRB1*1301 and HLA-DQB1*0201, showed a protective effect against primary DCM.
  • Two haplotypes, DRB1*0401/DQB1*0302 and DRB1*0401/DQB1*0401, were significantly associated with an increased risk of DCM.

Conclusions:

  • Variations in class II HLA alleles are implicated as a genetic factor in the susceptibility to primary DCM within the Tunisian population.
  • Specific HLA alleles and haplotypes may serve as biomarkers for DCM risk stratification.
  • Further research is warranted to elucidate the precise mechanisms underlying the HLA-DCM association.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...